Nubeqa® (Darolutamide)
Sequencing with Apalutamide

SUMMARY

  • No prospective studies have been identified in the published literature which specifically evaluate the sequencing of darolutamide and apalutamide.

  • The ARAMIS study (NCT02200614) was a randomized, double-blind, placebo-controlled phase 3 study (N=1509) that evaluated the efficacy and safety of darolutamide (n=955) vs placebo (n=554) in patients undergoing treatment with androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).1

    • Patients were excluded from enrollment in the ARAMIS study if they had prior treatment with a second-generation androgen receptor antagonist such as apalutamide.2

    • There is currently no information in the published literature regarding the use of apalutamide following darolutamide in those patients enrolled in the ARAMIS study.

  • The ARASENS study (NCT02799602) was an international, randomized, double-blind, placebo-controlled, phase 3 study (N=1306) that evaluated the efficacy and safety of darolutamide + ADT + docetaxel (n=651) vs placebo + ADT + docetaxel (n=655) in patients with metastatic, hormone-sensitive prostate cancer (mHSPC). 3

    • Patients were excluded from enrollment in the ARASENS study if they had prior treatment with a second-generation androgen receptor antagonist such as apalutamide.4

    • Among darolutamide patients who entered active or long-term follow-up for survival (n=315), 2 (0.6%) patients subsequently received apalutamide as a life-prolonging therapy. No efficacy or safety outcomes have been provided for these patients. 4

This page is intended for US healthcare professionals and may contain information outside of the approved prescribing information. It is provided in response to an unsolicited request. It is not intended as an endorsement of any usage not contained in the Prescribing Information. This response should be reviewed together with the current full Prescribing Information (including Boxed Warning) and Medical Safety Summary. These materials contain the approved indications, contraindications, warnings and precautions, adverse reactions, and other important safety information for Nubeqa® (Darolutamide).

Nubeqa is an androgen receptor inhibitor indicated for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC), and metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.

 

  • The ARANOTE study (NCT04736199) was a randomized, double-blind, placebo-controlled, phase 3 study (N=669) that evaluated the efficacy and safety of darolutamide 600 mg BID + ADT (n=446) vs placebo + ADT (n=223) in patients with mHSPC. 5

    • Patients were excluded from enrollment in the ARANOTE study if they had prior treatment with a second-generation androgen receptor antagonist such as apalutamide.5

    • Among darolutamide patients who discontinued study treatment (n=203), 3 patients subsequently received apalutamide as a life-prolonging therapy. No efficacy or safety outcomes have been provided for these patients.5

  • A multicenter, retrospective cohort study from Japan evaluated real-world outcomes of switching from apalutamide to another androgen receptor signaling inhibitor (ARSI). 6 Among 117 patients, 17 (14.5%) with either metastatic castration-sensitive prostate cancer (mCSPC) or nmCRPC switched because of rash. Four of these patients, all with nmCRPC, switched to darolutamide. Efficacy outcomes were not reported specifically for these 4 patients; rash was reported in 1 patient while receiving darolutamide.

 

LITERATURE SEARCH

A literature search of Embase® and/or PubMed® , and/or other external and internal resources was conducted pertaining to this topic on 28 September 2026.

 

REFERENCES

All the references were accessed on the literature search date.

  1. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, CastrationResistant Prostate Cancer. N Engl J Med. 2019;380(13):1235–1246. PMID: 30763142 https://www.ncbi.nlm.nih.gov/pubmed/30763142
  2. Supplement to: Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019;380(13):1235–1246. PMID: 30763142 https://www.nejm.org/doi/suppl/10.1056/NEJMoa1815671/suppl_file/nejmoa1815671_ap pendix.pdf
  3. Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, HormoneSensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132–1142. PMID: 35179323 https://www.ncbi.nlm.nih.gov/pubmed/35179323
  4. Supplement to: Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132– 1142. Accessed via https://www.nejm.org/doi/suppl/10.1056/NEJMoa2119115/suppl_file/nejmoa2119115_ap pendix.pdf
  5. Saad F, Vjaters E, Shore N, et al. Darolutamide in Combination With AndrogenDeprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol. 2024;42(36):4271–4281. PMID: 39279580 https://pubmed.ncbi.nlm.nih.gov/39279580/
  6. Tohi Y, Kato T, Fujiwara K, et al. Real-world efficacy of switching androgen receptor signaling inhibitor therapy following apalutamide discontinuation because of adverse events in advanced prostate cancer: a multicenter study. Jpn J Clin Oncol. 2026;56(3):345–351. PMID: 41449570 https://www.ncbi.nlm.nih.gov/pubmed/41449570